Marilyn Lewis

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Mike Westby, Caroline Smith‐Burchnell, Julie Mori et al. · Journal of Virology · 2006 · 346 citations

Phenotypic Susceptibility Assays, Immunology, Ccr5 Antagonist +16

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Mike Westby, Marilyn Lewis, Jeannette M. Whitcomb et al. · Journal of Virology · 2006 · 330 citations · Full text

Ccr5 Antagonist Maraviroc, Ccr5 Tropic, Human Retrovirus +11

Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients

Luke C. Swenson, Tingting Mo, Winnie Dong et al. · The Journal of Infectious Diseases · 2010 · 151 citations · Full text

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing

John Archer, Michael Braverman, Bruce E. Taillon et al. · AIDS · 2009 · 118 citations · Full text

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

Rachel A. McGovern, Alexander Thielen, Theresa Mo et al. · AIDS · 2010 · 115 citations